VasaPlex

VasaPlex

Coronary heart disease leading to acute myocardial infarction (MI; heart attack) is a principal cause of mortality worldwide. Cornerstone treatments for MI are designed to restore blood flow (i.e. to “reperfuse”) blocked coronary arteries. Despite reduced times to intervention, and successful stent placement, 30-50% of primary Percutaneous Coronary Intervention (PCI) patients exhibit low- or “no-reflow”, a phenomenon linked to poor outcomes, increased probability of heart failure, and death. Low/no-reflow occurs when macroscopic vessels are opened by stenting or thrombolysis, but distal myocardial perfusion remains compromised. Notably, even if they do not exhibit low- or no-reflow, nearly all patients will experience reperfusion injury after MI and PCI w/stenting.

Samba BioLogics, Inc., is providing new, innovative and effective products to improve patient survival, outcomes and quality of life after MI. In a large animal (pig) model of acute MI with reperfusion, intracoronary infusion of VasaPlex preserved 48 ± 12% of myocardial tissue at risk. At 24 hours after M, treatment with VasaPlex-F2 preserved epicardial electrical conduction across the region with infarction.

• Pre clinical large animal model of MI w/24 hr reperfusion (adult female pigs)
• PCI catheters/stents from UVM Medical Center (same used in patients with MI)